Tower Research Capital (TRC)’s PHAXIAM Therapeutics S.A.. American Depositary Shares PHXM Stock Holding History

Tower Research Capital (TRC)’s Portfolio PHXM Stock Details PHXM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-32	Closed	-$1K	–	6757
2021 Q4	$1K	Buy	32 +2	+7%	+$67	﹤0.01%	5939
2021 Q3	$2K	Buy	+30	New	+$1.68K	﹤0.01%	5331

Other funds holding PHXM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Tower Research Capital (TRC)'s PHXM Position: Q1 2022 in Review

Tower Research Capital (TRC) sold out of PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) in Q1 2022, closing a stake of 32 shares — an estimated $1K sold.

Tower Research Capital (TRC) first reported a position in PHXM in Q3 2021 and held it in 2 quarters. The position peaked at $2K in Q3 2021. 5 funds tracked by Wall St. Rank hold PHXM as of Q1 2022.

Tower Research Capital (TRC) reported no remaining PHAXIAM Therapeutics S.A.. American Depositary Shares position as of Q1 2022 after selling out during the quarter.
Tower Research Capital (TRC) sold 32 PHAXIAM Therapeutics S.A.. American Depositary Shares shares in Q1 2022, an estimated $1K.
Tower Research Capital (TRC) first reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares in Q3 2021 and held it in 2 quarters.
Tower Research Capital (TRC)'s PHAXIAM Therapeutics S.A.. American Depositary Shares position peaked at $2K in Q3 2021.
5 funds tracked by Wall St. Rank held PHAXIAM Therapeutics S.A.. American Depositary Shares as of Q1 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2022, filed 12 May 2022.